Search Results - "Rodallec, A."

Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles by Rodallec, A., Franco, C., Robert, S., Sicard, G., Giacometti, S., Lacarelle, B., Bouquet, F., Savina, A., Lacroix, R., Dignat-George, F., Ciccolini, J., Poncelet, P., Fanciullino, R.

“…Developing targeted nanoparticles is a rising strategy to improve drug delivery in oncology. Antibodies are the most commonly used targeting agents. However,…”
Get full text

Influence of HLA‐C environment on the spontaneous clearance of hepatitis C in European HIV–HCV co‐infected individuals by Legrand, N., David, G., Rodallec, A., Gaultier, A., Salmon, D., Cesbron, A., Wittkop, L., Raffi, F., Gendzekhadze, K., Retière, C., Allavena, C., Gagne, K.

“…Summary Natural killer (NK) cell functions are regulated by diverse inhibitory and activating receptors, including killer cell immunoglobulin‐like receptors…”
Get full text

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination by Lambert-Niclot, S, Allavena, C, Grude, M, Flandre, P, Sayon, S, Andre, E, Wirden, M, Rodallec, A, Jovelin, T, Katlama, C, Calvez, V, Raffi, F, Marcelin, A-G

“…In the context of a rilpivirine/emtricitabine/tenofovir disoproxil fumarate switch in HIV-1-infected patients with at least 1 year of virological success, we…”
Get full text

Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy by Allavena, C., Rodallec, A., Leplat, A., Hall, N., Luco, C., Le Guen, L., Bernaud, C., Bouchez, S., André-Garnier, E., Boutoille, D., Ferré, V., Raffi, F.

“…•Usefulness of HIV DNA genotype in virologically suppressed patients.•High concordance rate of mutations on reverse transcriptase and protease.•DNA genotype of…”
Get full text

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer [Erratum] by Rodallec, Anne, Sicard, Guillaume, Giacometti, Sarah, Carré, Manon, Pourroy, Bertrand, Bouquet, Fanny, Savina, Ariel, Lacarelle, Bruno, Ciccolini, Joseph, Fanciullino, Raphaelle

“…From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer [Erratum]Rodallec A, Sicard…”
Get full text

ERRATUM by A, Rodallec, G, Sicard, S, Giacometti

Get full text

ERRATUM by A, Rodallec, G, Sicard, S, Giacometti

Get full text

Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study) by Allavena, C., Volteau, C., André-Garnier, E., Guimard, T., Hall, N., Khatchatourian, L., Morrier, M., Billaud, E., Rodallec, A., Reliquet, V., Jovelin, T., Le Guen, L., Perré, P., Grégoire, M., Raffi, F.

“…•The SWAD study shows that switching from nevirapine to dolutegravir in combination with abacavir/lamivudine in 53 HIV-infected virologically controlled…”
Get full text

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer by Rodallec, Anne, Brunel, Jean-Michel, Giacometti, Sarah, Maccario, Helene, Correard, Florian, Mas, Eric, Orneto, Caroline, Savina, Ariel, Bouquet, Fanny, Lacarelle, Bruno, Ciccolini, Joseph, Fanciullino, Raphaelle

“…Trastuzumab plus docetaxel is a mainstay to treat HER2-positive breast cancers. However, developing nanoparticles could help to improve the efficacy/toxicity…”
Get full text

HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition by Jouand, Nicolas, Bressollette-Bodin, Céline, Gérard, Nathalie, Giral, Magali, Guérif, Pierrick, Rodallec, Audrey, Oger, Romain, Parrot, Tiphaine, Allard, Mathilde, Cesbron-Gautier, Anne, Gervois, Nadine, Charreau, Béatrice

“…Immune response against human cytomegalovirus (HCMV) includes a set of persistent cytotoxic NK and CD8 T cells devoted to eliminate infected cells and to…”
Get full text

Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination by Lefebvre, Maeva, Secher, Solène, Bouchez, Sabelline, Vandamme, Yves-Marie, Fialaire, Pascale, Leautez, Sophie, Blanchi, Sophie, Michau, Christophe, Coste-Burel, Marianne, Brunet-Cartier, Cécile, Reliquet, Véronique, Gregoire, Antoine, Raffi, François, Allavena, Clotilde

“…Widespread use of the measles vaccine should lead to the elimination of this disease. Here we study the seroprevalence of measles in a cohort of adults living…”
Get full text

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer by Rodallec, Anne, Sicard, Guillaume, Giacometti, Sarah, Carré, Manon, Pourroy, Bertrand, Bouquet, Fanny, Savina, Ariel, Lacarelle, Bruno, Ciccolini, Joseph, Fanciullino, Raphaelle

“…Nanoparticles are of rising interest in cancer research, but in vitro canonical cell monolayer models are not suitable to evaluate their efficacy when…”
Get full text

Reaching the Second and Third Joint United Nations Programme on Human Immunodeficiency Virus (HIV)/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary HIV Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort by Le Guillou, Adrien, Pugliese, Pascal, Raffi, François, Cabie, André, Cuzin, Lise, Katlama, Christine, Allavena, Clotilde, Drame, Moustapha, Cotte, Laurent, Bani-Sadr, Firouzé

“…Abstract Background In late 2013, France was one of the first countries to recommend initiation of combination antiretroviral therapy (cART) irrespective of…”
Get full text

Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population by Allavena, C, Mounoury, O, Rodallec, A, Reliquet, V, Billaud, E, Raffi, F

Get more information

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial by Babiker, Abdel, Castro nee Green, Hannah, Compagnucci, Alexandra, Fiscus, Susan, Giaquinto, Carlo, Gibb, Diana M, Harper, Lynda, Harrison, Linda, Hughes, Michael, McKinney, Ross, Melvin, Ann, Mofenson, Lynne, Saidi, Yacine, Smith, M Elizabeth, Tudor-Williams, Gareth, Walker, A Sarah

“…Summary Background Children with HIV will be on antiretroviral therapy (ART) longer than adults, and therefore the durability of first-line ART and timing of…”
Get full text

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination by Lambert-Niclot, S., Allavena, C., Grude, M., Flandre, P., Sayon, S., Andre, E., Wirden, M., Rodallec, A., Jovelin, T., Katlama, C., Calvez, V., Raffi, F., Marcelin, A.-G.

Get full text

Reaching the Second and Third Joint United Nations Programme on Human Immunodeficiency Virus (HIV)/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary HIV Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort by Le Guillou, Adrien, Pugliese, Pascal, Raffi, François, Cabie, André, Cuzin, Lise, Katlama, Christine, Allavena, Clotilde, Drame, Moustapha, Cotte, Laurent, Bani-Sadr, Firouzé, Orticoni, M, Soavi, M, Luquet- Besson, I, Ressiot, E, Carta- Padovani, M, Ducassou, M, Bertone, H, Galie, S, Galinier, A, Monclar, M, Ritleng, A, Ivanova, A, Blanco-Betancourt, C, Lions, C, Poizot-Martin, I, Dhiver, C, Saadia Mokhtari, M, Ménard, A, Tissot Dupont, H, Toméi, C, Meddeb, L, Belkhir, A, Ravaux, I, Alvarez, M, Biezunski, N, Debard, A, Delpierre, C, Lansalot, P, Lelièvre, L, Martin-Blondel, G, Piffaut, M, Porte, L, Saune, K, Delobel, P, Pugliese, P, Breaud, S, Ceppi, C, Chirio, D, Cua, E, Dellamonica, P, Demonchy, E, de Monte, A, Durant, J, Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V, Allavena, C, Bernaud, C, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet-Cartier, C, Deschanvres, C, Gaborit, B, Hall, N, Jovelin, T, Le Turnier, P, Morineau, P, Reliquet, V, Sécher, S, Cavellec, M, Soria, A, Ferré, V, André-Garnier, E, Rodallec, A, Lefebvre, M, Grossi, O, Aubry, O, Raffi, F, Amazzough, K, Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C, Consigny, P, Danion, F, Dureault, A, Duvivier, C, Goesch, J, Guery, R, Henry, B, Jidar, K, Lanternier, F, Loubet, P, Lortholary, O, Louisin, C

“…Background In late 2013, France was one of the first countries to recommend initiation of combination antiretroviral therapy (cART) irrespective of CD4 cell…”
Get full text

Risk of diabetes in HIV‐infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort by Provoost, A., Dramé, M., Cotte, L., Cuzin, L., Garraffo, R., Rey, D., Raffi, F., Poizot‐Martin, I., Pugliese, P., Enel, P., Obry‐Roguet, V., Faucher, O., Bregigeon, S., Ménard, A., Biezunski, N., Cuzin, L., Delobel, P., Fourcade, C., Porte, L., Mularczyk, M., Garipuy, D., Lepain, I., Marcel, M., Metsu, D., Puntis, E., Pugliese, P., Ceppi, C., Cottalorda, J., Ferrando, S., Fuzibet, J. G., Garraffo, R., Naqvi, A., Perbost, I., Pillet, S., Prouvost‐Keller, B., Pradier, C., Roger, P. M., Rosenthal, E., Dellamonica, P., Raffi, F., Bonnet, B., Brunet, C., Jovelin, T., Bernaud, C., Morineau, P., Reliquet, V., Hüe, H., Cavellec, M., Soria, A., André‐Garnier, E., Rodallec, A., Ferré, V., Leguen, L., Lefebvre, M., Jacomet, C., Cheret, A., Choisy, P., Duvivier, C., Valantin, M. A., Agher, R., Katlama, C., Isnard‐Bagnis, C., Peytavin, G., Joly, V., Yazdanpanah, Y., Cabié, A., Pierre‐François, S., Liautaud, B., Fischer, P., Cheneau, C., Priester, M., Bernard‐Henry, C., de Mautort, E., May, T., Hoen, B., Chirouze, C., Gardiennet, Q., Bani‐Sadr, F., Berger, J. L., N'Guyen, Y., Lambert, D., Lebrun, D., Kmiec, I., Brodard, V., Cotte, L., Chidiac, C., Ferry, T., Ader, F., Biron, F., Boibieux, A., Miailhes, P., Perpoint, T., Schlienger, I., Braun, E., Koffi, J., Longuet, C., Guéripel, V., Augustin‐Normand, C., Degroodt, S., Peyramond, D.

“…Summary Background Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections have been reportedly associated with a higher risk of…”
Get full text

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017 by Wirden, Marc, De Oliveira, Fabienne, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Chaix, Marie-Laure, Raymond, Stéphanie, Si-Mohammed, Ali, Alloui, Chakib, André-Garnier, Elisabeth, Bellecave, Pantxika, Malve, Brice, Mirand, Audrey, Pallier, Coralie, Poveda, Jean-Dominique, Rabenja, Theresa, Schneider, Veronique, Signori-Schmuck, Anne, Stefic, Karl, Calvez, Vincent, Descamps, Diane, Plantier, Jean-Christophe, Marcelin, Anne-Genevieve, Visseaux, Benoit

“…BackgroundEnding the HIV pandemic must involve new tools to rapidly identify and control local outbreaks and prevent the emergence of recombinant strains with…”
Get full text

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice by Gantner, Pierre, Bani-Sadr, Firouze, Garraffo, Rodolphe, Roger, Pierre-Marie, Treger, Michèle, Jovelin, Thomas, Pugliese, Pascal, Rey, David

“…To assess immunovirological response, safety and pharmacokinetic of NRTI-sparing regimen dual therapy of atazanavir (ATV) and raltegravir (RAL) in maintenance…”
Get full text